A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc‑Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B‑Cell Non-Hodgkin’s Lymphoma: Long-Term Follow-up, Final Analysis